BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang H, Li Q, Yu S, Yu Y, Wang Y, Li W, Cui Y, Liu T. Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis. Clin Transl Oncol 2017;19:197-203. [PMID: 27324991 DOI: 10.1007/s12094-016-1523-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Visal TH, den Hollander P, Cristofanilli M, Mani SA. Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'? Br J Cancer 2022. [PMID: 35273384 DOI: 10.1038/s41416-022-01768-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wang WC, Zhang XF, Peng J, Li XF, Wang AL, Bie YQ, Shi LH, Lin MB, Zhang XF. Survival Mechanisms and Influence Factors of Circulating Tumor Cells. Biomed Res Int 2018;2018:6304701. [PMID: 30515411 DOI: 10.1155/2018/6304701] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
3 Li Q, Peng K, Chen E, Jiang H, Wang Y, Yu S, Li W, Yu Y, Liu T. IntegrinB5 upregulated by HER2 in gastric cancer: a promising biomarker for liver metastasis. Ann Transl Med 2020;8:451. [PMID: 32395495 DOI: 10.21037/atm.2020.03.184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li Q, Li H, Jiang H, Feng Y, Cui Y, Wang Y, Ji Y, Yu Y, Li W, Xu C, Yu S, Zhuang R, Liu T. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study. Clin Transl Oncol 2018;20:695-702. [DOI: 10.1007/s12094-017-1772-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
5 Hackshaw MD, Bui CL, Ladner A, Tu N, Islam Z, Ritchey ME, Salas M. Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumab. Cancer Treat Res Commun 2020;24:100189. [PMID: 32673845 DOI: 10.1016/j.ctarc.2020.100189] [Reference Citation Analysis]
6 Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, Tang L, Xin Y, Jin J, Zhang YJ, Yuan XL, Liu TS, Li GX, Wu Q, Xu HM, Ji JF, Li YF, Wang X, Yu S, Liu H, Guan WL, Xu RH. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019;39:10. [PMID: 30885279 DOI: 10.1186/s40880-019-0349-9] [Cited by in Crossref: 123] [Cited by in F6Publishing: 120] [Article Influence: 41.0] [Reference Citation Analysis]
7 Li HK, Morokoshi Y, Kodaira S, Kusumoto T, Minegishi K, Kanda H, Nagatsu K, Hasegawa S. Utility of 211At-trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically-relevant Mouse Model. J Nucl Med 2021:jnumed. [PMID: 33547212 DOI: 10.2967/jnumed.120.249300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]